WO2006021974A1 - A process for synthesizing diol (viii)-an intermediate of montelukast sodium - Google Patents

A process for synthesizing diol (viii)-an intermediate of montelukast sodium Download PDF

Info

Publication number
WO2006021974A1
WO2006021974A1 PCT/IN2005/000280 IN2005000280W WO2006021974A1 WO 2006021974 A1 WO2006021974 A1 WO 2006021974A1 IN 2005000280 W IN2005000280 W IN 2005000280W WO 2006021974 A1 WO2006021974 A1 WO 2006021974A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
ketoester
alcohol
benzaldehyde
ketone
Prior art date
Application number
PCT/IN2005/000280
Other languages
French (fr)
Inventor
Sanjay Suri
Gurdeep Singh Sarin
Manu Mahendru
Original Assignee
Morepen Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morepen Laboratories Limited filed Critical Morepen Laboratories Limited
Publication of WO2006021974A1 publication Critical patent/WO2006021974A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals

Definitions

  • This invention relates to A Process for Synthesizing
  • This invention relates to a process for synthesizing intermediates of Montelukast Sodium, which is a potential leukotriene antagonist.
  • the present invention particularly, relates to a process whereby the intermediates of Montelukast sodium are produced in high yields and high purity.
  • the present invention more particularly relates to a process that is cost effective, environment and user friendly. Further, the process disclosed in this invention is more compatible to the economics of manufacturing of the title compounds and can be scaled up eventually leading to the commercialization of a process for the manufacture of Montelukast Sodium advantageously.
  • Montelukast Sodium which can be described chemically as [R-(E)]-l-[[[l-[3- [2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(l -hydroxy- 1 - methylethyl)phenyl]propyl] thio]methyl]cyclopropaneacetic acid, monosodium salt, and structurally by formula as given below, being a leukotriene antagonist is useful to treat, prevent or ameliorate in mammals especially in human beings: (i) pulmonary disorders including asthma, chronic bronchitis and related obstructive airway diseases, (ii) allergies and allergic reactions such as allergic rhinitis, contact dermatitis conjunctivitis and the like, (iii) arthritis inflammation or inflammatory bowel diseases, (iv) skin disorders, (v) cardiovascular disorders, (vi) ocular conditions like uveitis, cerebral
  • step (h) alkylating the acid in the above mixture into the corresponding ketoester VI
  • step (h) reducing the ketoester VI asymmetrically to chiral alcohol VII
  • step (i) converting the chiral alcohol obtained in step (h) to title compound.
  • Methods for the preparation of benzaldehyde are described in US Patent No. 4,851,4 09 ('409) and US Patent No. 5,8 69,673 ('673).
  • diol VIII is a key advanced intermediate for two of the several synthetic routes being pursued for assembling the basic skeleton of montelukast sodium.
  • the purity of diol VIII is very critical in order to crystallize further intermediate such as mesylate in the process of synthesizing Montelukast sodium, other wise it does not precipitate out even after seeding or stirring for longer duration at low temperatures. Higher the purity of the diol VIII, faster is the crystallization of the mesylate.
  • the quality of diol (VIH) in turn depends on the quality of the precursor's keto ester (VI) and hydroxyl ester
  • the diol VIII is generally prepared from chiral alcohol ester VII, represented chemically as Metliyl-[(E)-2-[3-[3-[2-[7-chloro-2-quinolinyl) ethenyl]phenyl]-3- hydroxypropyl]benzoate (VII), via Cerium chloride assisted double addition of methylmagnesium chloride a which in turn is generated through asymmetric reduction of the intermediate ketoester Methyl-[E]-2-[3-[3-[2-(7-chloro -2- quinolinyl) ethenyl]phenyl]-3-oxopropyl]benzoate (VI).
  • ketoester VI
  • hydroxyl ester VII
  • diol VIH
  • organometallic routes offer advantages of short step synthesis over the conventional route, the difficulties associated in synthesizing the desired halogen substituted aromatic intermediates, low yield and high cost of the organometallic complexes as well as the stringent and critical reaction parameters like anhydrous and inert, oxygen-free atmosphere employed therein make the process inconvenient and commercially unviable. Further, the presence of additional inorganic salts used in the reaction, poses problems in the isolation of ketoester.
  • Tedious aqueous extractive workup procedures invoving special filtration techniques or repeated filtration through hyflow are needed to remove the organometallic complexes whose presence in the intermediate is likely to influence the reaction kinetics or the quality of product formation in the following stages Specifically, in this case, the intermediate vinyl alcohol (III) to the ketoester (IV) conversion, the palladium catalyzed Heck coupling is performed in the presence of a mixture of Lithium salts and phase transfer reagents.
  • the conventional process for synthesizing Methyl-[E]-2-[3-[3-[2-(7-chloro-2- quinolinyl] ethenyl]phenyl]-3-oxopropyl]benzoate (VI) is a multistep step (6) sequence and involves the selective condensation of 7-Chloroquanaldine with isophthaldehyde in the presence of acetic anhydride under controlled stochiometric conditions to form the intermediate [E]-3-2-(7-chloro-2-quinolinyl) ethenyl]benzaldehyde (I), which upon reaction with methyl magnesium chloride or bromide in tetrahydrofuran (THF) followed by activated manganese dioxide assisted oxidation of the resulting [E]-l-[3-]2-(7-Chloro-2-quinolinyl) ethenyl]phenyl]ethanol (II) affords the aromatic ketone intermediate III in low yield.
  • ketone III is then benzylated with Methyl-2-bromomethyl or iodomethyl benzoate in the presence of lithium diisopropylamide at low temperatures to directly form ketoester Methyl-[E]-2-[3-[3-[2-(7-chlorq-2-quinolinyl)ethenyl]phenyl]-3- oxopropyl]benz-oate (VI) in low yields which has to be chromatographically purified in order to remove the dibenzylated compound and other impurities that are formed in appreciable amounts.
  • the crude ketoester VI can be prepared in relatively higher yields via a three step route in which the ketone III sequentially undergoes facile sodium hydride induced one carbon homologation with dimethyl carbonate followed again by sodium hydride assisted benzylation of
  • one of the main objects of the present invention is to provide a process, which obviates the drawbacks associated with the existing processes.
  • the other objective is to provide a process that is simple, easy to operate, environment friendly and high yielding.
  • Still another object of the present invention is to develop an alternate, milder and scaleable process for synthesizing ⁇ ketoester (IV) eliminating employing additional inorganic salts and phase transfer reagents.
  • Still another objective of the invention is to develop reproducible reaction conditions for the preparation of chiral alcohol VII via asymmetric reduction of benzylated ketoester (VI) using reduced amount of the expensive chiral reagent (-) diisopinocamphenylchloro borane.
  • Further objective of the present reaction is to develop an alternative workup procedure for the isolation of diol (VIII), in which the problems associated with the delays encountered during de-emulsification of the reaction work up are eliminated.
  • homologation of the said ketone III with dialkyl carbonate can be successfully achieved by substituting the moisture and temperature sensitive and explosive alkali metal hydride with milder agents such as alkali metal alkoxide.
  • the benzylation also can be affected in presence of mild bases avoiding use of sodium hydride.
  • the reaction is preferably performed in 1, 4-dioxane in the presence of sodium methoxide at 75-8O 0 C.
  • the present invention provides a process for synthesizing diol (VIII)- an intermediate of Montelukast Sodium which comprises:
  • ketoester (c) subjecting the said alcohol to Heck coupling with methyl-2-iodobenzoate in presence of Lewis base, acetonitrile, and palladium acetate to yield ketoester
  • a process for synthesizing ketoester (V ⁇ )-an intermediate of Montelukast Sodium which comprises: (a) preparing benzaldehyde of formula I in a conventional manner,
  • step (f) asymmetrically reducing the ketoester of formula VI, to a chiral alcohol of formula VII using (-) diisopinocamphenylchloroborane (-DIPC1) in presence of less than 4 times v/w aprotic solvent and optionally in presence of Lewis base with respect to the said ketoester of formula VI,
  • the reaction in step (a) may be carried out in presence of acetic anhydride at a temperature in the range of 90- 15O 0 C for a period of 10-30 hrs., preferably at 100-110 0 C for 12-15 hrs.
  • Grignard reagent used may be of
  • R 1 MgX where R 1 is alkyl with Cl to C4 exemplified by methyl, ethyl,
  • X is halide preferably iodide
  • reaction being carried out in presence of ethereal solvent including but not restricted to 2-methoxytetrahydrofuran, tetrahydropyran, 1, 2-dimethoxyethane, 1, 2-diethoxy -ethane, preferably tetrahydrofuran or mixture thereof, at a temperature ranging from -25 to +4O 0 C, preferably at -5 to +1O 0 C.
  • ethereal solvent including but not restricted to 2-methoxytetrahydrofuran, tetrahydropyran, 1, 2-dimethoxyethane, 1, 2-diethoxy -ethane, preferably tetrahydrofuran or mixture thereof, at a temperature ranging from -25 to +4O 0 C, preferably at -5 to +1O 0 C.
  • the direct isolation and crystallization of the alcohol of formula II after workup was effected by adding calculated amount of 1 to 25% preferably 2 to 10% more preferably 10% aqueous soution of ammonium salt such as ammonium acetate, ammonium chloride, preferably ammonium chloride solution in an amount of 2 to 10 preferably 3 to 5 times of benzaldehyde (I) and water in the range of 5 to 50 preferably 10 to 15 times of benzaldehyde (I) to the reaction mixture and then straightaway crystallizing the product by stirring the mixture at -10 0 C to 35 0 C preferably 5 0 C -1O 0 C for extended period of 2 to 10 preferably 4 to 8 hours, then isolating by centrifugation, filtration and drying.
  • ammonium salt such as ammonium acetate, ammonium chloride, preferably ammonium chloride solution in an amount of 2 to 10 preferably 3 to 5 times of benzaldehyde (I) and water in the range of 5 to 50
  • Another embodiment of the invention is that the oxidation of alcohol (II) in step (b) being performed under Swern's conditions employing oxalyl chloride, dimethyl sulfoxide and Lewis base exemplified by alkyl amine such as triethyl amine, tri n-propylamine, tri n-butylamine, tri n-pentylamine, and diisopropyl ethyl amine preferably triethyl amine of 5 to 15 molar preferably 8 to 12 molar equivalents w. r.
  • alkyl amine such as triethyl amine, tri n-propylamine, tri n-butylamine, tri n-pentylamine, and diisopropyl ethyl amine preferably triethyl amine of 5 to 15 molar preferably 8 to 12 molar equivalents w. r.
  • step (c) may be effected by milder bases of formula R 3 OM wherein R 3 is alkyl
  • M is Na or K selected from alkali metal alkoxide including sodium methoxide, sodium ethoxide, sodium n-propoxides, sodium n- isopropoxide, sodium n-butoxides, sodium isobutoxide, sodium tertiary butoxide as well as their potassium salt derivatives in an amount of 1.5 to 7 molar equivalents w. r. t.
  • alkyl may be with Cl to C3 in an amount ranging from 2 to 8 preferably 3 to 4 molar equivalents of ketone, in polar solvents like THF, 1,2 dimethoxyethane, 1,2 diethoxyethane, dimethyl formamide, dimethyl acetamide preferably 1,4-dioxane in an amount of 2 to 10 v/w with regard to ketone at 10 to 100 0 C, preferably at 40 to 9O 0 C more preferably at 60 to 9O 0 C , still more preferably at 70 to 8O 0 C.
  • polar solvents like THF, 1,2 dimethoxyethane, 1,2 diethoxyethane, dimethyl formamide, dimethyl acetamide preferably 1,4-dioxane in an amount of 2 to 10 v/w with regard to ketone at 10 to 100 0 C, preferably at 40 to 9O 0 C more preferably at 60 to 9O 0 C , still more preferably at 70 to 8O
  • the benzylation of the ⁇ -ketoester of formula IV in step (d) may be performed by reacting the said ketoester with alkyl- 2- halomethylbenzoate preferably methyl or ethyl and n-propyl ester derivative and halo may be chloro, bromo or iodo particularly alkyl-2-bromomethylbenzoate using much milder and safer alkali metal bases like sodium or potassium carbonates in polar aprotic solvents like dimethylformamide, dimethylacetamide, dimethylsulfoxide, hexamethylphosphorous-triamide, 1, 4 - dioxane, tetrahydrofuran, 1, 2- dimethoxyethane and 1, 2 - diethoxy -ethane etc.
  • alkyl- 2- halomethylbenzoate preferably methyl or ethyl and n-propyl ester derivative
  • halo may be chloro, bromo or iodo particularly alkyl-2
  • step (d) is carried out using a mixture of acetic acid and hydrochloric acid in a known manner.
  • the purification may be carried out by crystallizing with 8 to 12 times acetonitrile, or with a mixture of dichloromethane and methanol 4 to 15 preferably 7 to 10 times v/w each w.r.t. ketoester.
  • the asymmetrical reduction of the ketoester VI to chiral alcohol VII may be effected by employing 1.2 to 2.0 eq.
  • aprotic solvent exemplified by ethers such as diethyl ether, diisopropyl ether, di n-butyl ether, diisopentyl ether, anisole, cyclic ethers such as tetrahydropyran, 2- methyltetrahydrofuran, and 2-ethoxyfuran, most preferably tetrahydrofuran and the Lewis bases that may be used include but are not limited to alkyl amine like triethylamine, tri n-propylamine, tri n-butylamine, trisopropylamine, triisobutylamine, most preferably diisopropylethylamine in 0.25 to 2 molar equivalents, preferably 0.5 to 0.75 molar equivalents w.
  • ethers such as diethyl ether, diisopropyl ether, di n-butyl ether, diisopentyl ether, anisole, cyclic ethers such as
  • the cerium halo salt and alkylmagnesium halide used for converting the chiral alcohol VII to the diol intermediate VIII may be such as methyl or ethyl and propylmagnesium chlorides, bromides or iodides and the isolation may be undertaken by simply dumping the reaction mass into as stirred suspension of hyflow supercel in 8 to 10% ammonium salt preferably ammonium chloride followed by centrifuging or filtering through a bed of hyflow supercel.
  • the procedure may also be carried out in the presence of water immiscible organic solvents like benzene, toluene, ortho or para xylene, and halogenated solvents like methylene dichloride, chloroform, and 1,2-dichloro ethane, which may be used in pure form or as mixtures in any suitable composition.
  • water immiscible organic solvents like benzene, toluene, ortho or para xylene
  • halogenated solvents like methylene dichloride, chloroform, and 1,2-dichloro ethane
  • the Lewis base used in Heck coupling of alcohol (II) in step (c) include but are not limited to alkyl amines like triethylamine, tri n-propylamine, tri n-butylamine, diisopropyl ethyl amine, in an amount of 0.1 to 10 times preferably 0.5 to 1 times, palladium acetate used may vary from 0.1% w/w to 2.5 % w/w, preferably
  • 0.5 to 1.5% w/w and the amount of acetonitrile may vary between 1 and 100 times, preferably 3 and 10 times v/w w. r. t the benzaldehyde (I) used.
  • the reaction may be performed at 10 to 100 0 C, preferably at 65 to 75 0 C over a period of 1 to 100 hrs, preferably for 5 to 25 hrs.
  • the invention is further illustrated with the help of examples. However, this should not construe the scope of the invention. Any deviation from this, apparent and or obvious to an ordinary skilled person in the field forms a part of this invention though not explicitly substantiated.
  • IR spectrum was recorded on NICOLET- AVAATAR 320 FTIR spectrophotometer, 1 H-NMR (300 MHz) and 13 C-NMR (75.47 MHz) spectra were measured on Bruker DPX-300 spectrometer at ambient temperatures.
  • EIMS spectrum were recorded onVG-70-250S mass spectrometer at NEPER, Mohalli, Punjab and RSIC, Punjab University, Chandigarh, India.
  • the condensed product was filtered, washed with hexane (100ml) and dried at 50 to 6O 0 C for 4 to 6 hours.
  • the crude product (158 g) and ethyl acetate (2.37 It) were charged in a round bottomed flask and heated to reflux with stirring at 60 to 7O 0 C for 30 minutes.
  • the hot solution was filtered through cloth and the filtrate was concentrated to almost half the volume (i.e. approximately 7 It) under vacuum.
  • Step 1 To a 2.1t/4 neck round bottom flask, fitted with mechanical stirrer, thermometer pocket and reflux condenser were successively charged glacial acetic acid (585 ml), concentrated hydrochloric acid (117 ml), Methyl-[E]-2-[3-
  • Step 2 To a 3 lt/4 neck round bottom flask, fitted with a mechanical stirrer, thermometer pocket, and reflux condenser were successively charged acetone (1.28 It), K 2 CO 3 (40 g, 0.29 mol), step 1 product ( 107 g, 0.24 mol)and methyl iodide (31.5 g, 13.8 ml, 0.22 mol) at 25 to 30 0 C and the reaction mixture was slowly heated to 50 to 55 0 C and stirred for 6 to 8 hours. After the reaction was over( as monitored by TLC), the mixture was filtered through hyflow bed to remove the precipitated inorganic salts and the bed was washed with acetone (255 ml).
  • Step 3 -Puriflcation of crude keto ester CVD :
  • Method I To a 1 lt/3 neck round bottom flask fitted with a mechanical stirrer and a thermometer pocket were charged the above crude Methyl-[E]-2-[3-[3-[2-(7-chloro-2- quinolinyl)ethenyl]phenyl]-3-oxopropyl]benzoate (VI) obtained in step 2 (45 g, ), dichloromethane (225 niL) and the mixture was stirred at 38 to 40 0 C for 15 minutes, during which, complete dissolution of solid took place.
  • EXAMPLE 9 Preparation of [E]-l-[3-[2-(7-ChIoro-2-quinolinyl)ethenyl]phenyl]-2-propen- l-ol (II): To a cooled (-10 to 0 0 C) and stirred suspension of [E]-3-2-(7-Chloro-2- quinolinyl)ethenyl]benzaldehyde (I) (10Og, 0.34 mol) in tetrahydrofuran (300 rnL) and toluene (1000 mL) in a 3.0 lt/4 neck round bottomed flask fitted with a mechanical stirrer, thermometer pocket and calcium chloride drying tube under nitrogen gas atmosphere, vinylmagnesium bromide (500 g, , approx.
  • the process is high yielding .
  • the process is cost effective user friendly, environmentally clean.

Abstract

A process comprises preparing benzaldehyde of formula I in a conventional manner, reacting the said benzaldehyde I with Grignard reagent in water miscible etheral solvent to precipitate the alcohol of formula (II) by addition of ammonium salt and water followed by isolating the alcohol thus precipitated by any known methods and then oxidizing directly under 'Swern's conditions' to get a ketone of formula m, enolizing the said ketone in presence of a mild base such as alkali metal alkoxide and then reacting it with dialkyl carbonate under conditions effective to yield a β- ketoester of formula IV, benzylating the said β-ketoester so obtained in the preceding step to form the benzoate of formula V in presence of mild inorganic base followed by decarboxylating the said benzoate to a mixture of a ketoester of formula VI and its corresponding acid of formula VIA in the presence of acidic conditions, alkylating the acid VIA present in the mixture in the preceding step to obtain ketoester of formula VI and purifying it if so desired, asymmetrically reducing the ketoester of formula VI, to a chiral alcohol of formula VII using (-) diisopinocamphenylchloroborane (-DIPC1) in presence of less than 4 times v/w aprotic solvent and optionally in presence of Lewis base with respect to the said ketoester of formula VI, treating the said chiral alcohol VII with cerium halo salt, and alkylmagnesium halide followed by isolating the title compound using hyflow supercel and ammonium chloride to get the intermediate diol of formula VIII. Atemately, the said alcohol to Heck coupling with methyl-2-iodobenzoate in presence of Lewis base, acetonitrile, and palladium acetate to yield ketoester (VI), which is converted to diol (VIII) as described herein above.

Description

This invention relates to A Process for Synthesizing
Intermediates of Montelukast Sodium
FIELD OF THE INVENTION:
This invention relates to a process for synthesizing intermediates of Montelukast Sodium, which is a potential leukotriene antagonist. The present invention particularly, relates to a process whereby the intermediates of Montelukast sodium are produced in high yields and high purity. The present invention more particularly relates to a process that is cost effective, environment and user friendly. Further, the process disclosed in this invention is more compatible to the economics of manufacturing of the title compounds and can be scaled up eventually leading to the commercialization of a process for the manufacture of Montelukast Sodium advantageously. BACKGROUND OF THE INVENTION: Montelukast Sodium, which can be described chemically as [R-(E)]-l-[[[l-[3- [2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(l -hydroxy- 1 - methylethyl)phenyl]propyl] thio]methyl]cyclopropaneacetic acid, monosodium salt, and structurally by formula as given below, being a leukotriene antagonist is useful to treat, prevent or ameliorate in mammals especially in human beings: (i) pulmonary disorders including asthma, chronic bronchitis and related obstructive airway diseases, (ii) allergies and allergic reactions such as allergic rhinitis, contact dermatitis conjunctivitis and the like, (iii) arthritis inflammation or inflammatory bowel diseases, (iv) skin disorders, (v) cardiovascular disorders, (vi) ocular conditions like uveitis, cerebral disorder, (vii) glomerular nephritis, (viii) hepatitis and allograft rejections.
Figure imgf000003_0001
Montelukast Sodium
The process for the preparation of [(E)]-2-[3(S)-[3-[2-(7-Chloro-2-quinolinyl)- ethenyl]phenyl]-3-hydroxypropyl]phenyl]-2-propanol (VIII) ( refered as diol) is described in US 5, 565, 473 and US 5, 614, 632) and schematically represented in Figure 1 in the drawing accompanying the provisional specification, generally, comprises of following steps:
(a) condensing 7-Chloroquinaldine with isophthaldehyde to yield benzaldehyde I,
(b) converting the said benzaldehyde I into secondary alcohol II,
(c) oxidizing the alcohol thus obtained to aromatic ketone III,
(d) enolizing the ketone to β-ketoester IV
(e) benzylating the β-ketoester into benzoate V,
(f) decarboxylating the benzoate so obtained to a mixture of ketoester VI and its corresponding acid VIA,
(g) alkylating the acid in the above mixture into the corresponding ketoester VI (h) reducing the ketoester VI asymmetrically to chiral alcohol VII and finally (i) converting the chiral alcohol obtained in step (h) to title compound. Methods for the preparation of benzaldehyde are described in US Patent No. 4,851,4 09 ('409) and US Patent No. 5,8 69,673 ('673).
In the process of synthesis of Montelukast Sodium, diol VIII is a key advanced intermediate for two of the several synthetic routes being pursued for assembling the basic skeleton of montelukast sodium. The purity of diol VIII is very critical in order to crystallize further intermediate such as mesylate in the process of synthesizing Montelukast sodium, other wise it does not precipitate out even after seeding or stirring for longer duration at low temperatures. Higher the purity of the diol VIII, faster is the crystallization of the mesylate. The quality of diol (VIH) in turn depends on the quality of the precursor's keto ester (VI) and hydroxyl ester
(VH). The diol VIII is generally prepared from chiral alcohol ester VII, represented chemically as Metliyl-[(E)-2-[3-[3-[2-[7-chloro-2-quinolinyl) ethenyl]phenyl]-3- hydroxypropyl]benzoate (VII), via Cerium chloride assisted double addition of methylmagnesium chloridea which in turn is generated through asymmetric reduction of the intermediate ketoester Methyl-[E]-2-[3-[3-[2-(7-chloro -2- quinolinyl) ethenyl]phenyl]-3-oxopropyl]benzoate (VI).
Therefore, in the whole process leading to superior grade Montelukast sodium in an economically feasible process, quality of the intermediates such as ketoester (VI), hydroxyl ester (VII) and diol (VIH) play a very important role. In US-5, 565, 473 and EP-480, 717, several conventional and organo-metallic routes for synthesizing the ketoester VI have been described. In most of the routes involving organometallic reagents, Palladium catalyzed Heck coupling has been employed as the key element for assembling the backbone of the aromatic ring system. Although the organometallic routes offer advantages of short step synthesis over the conventional route, the difficulties associated in synthesizing the desired halogen substituted aromatic intermediates, low yield and high cost of the organometallic complexes as well as the stringent and critical reaction parameters like anhydrous and inert, oxygen-free atmosphere employed therein make the process inconvenient and commercially unviable. Further, the presence of additional inorganic salts used in the reaction, poses problems in the isolation of ketoester. Tedious aqueous extractive workup procedures invoving special filtration techniques or repeated filtration through hyflow are needed to remove the organometallic complexes whose presence in the intermediate is likely to influence the reaction kinetics or the quality of product formation in the following stages Specifically, in this case, the intermediate vinyl alcohol (III) to the ketoester (IV) conversion, the palladium catalyzed Heck coupling is performed in the presence of a mixture of Lithium salts and phase transfer reagents. Moreover the presence of even small amount of palladium metal and its complexes in the synthesized ketoester VI considerably reduces the options for generating pure chiral alcohol/hydroxy ester VII, since reduction of the double bond also occurs while carrying out asymmetric reduction of the keto group in the presence of chloroborane methyl sulfide (CBS) complex (Please see J. Med. Chem.; 58, 3733, 1993). This necessitates the use of (-) Diisopinocamphenylchloroborane, a not so stable and difficult to synthesize reagent that has to be used in more than molar equivalence for the completion of the reaction. In the case of conversion of keto ester (IV) into hydroxy ester (V) problems were encountered as the reaction did not go to completion when performed as per the reported experimental conditions in THF ( US-5, 565, 473, US-5, 545, 758 and US- 5, 693, 816). Very often it was observed that once the reaction stops after 50-75% conversion had taken place in the presence of the desired quantity of (-) DIPCl, the reaction could not be made to go to completion by adding additional 2 or more equivalents of the reagent and even after extended periods of stirring. The borane reagent (-) DIPCl is highly sensitive to both oxygen and water and the process requires stringent operational conditions such as inert or anaerobic atmosphere there by making the process complex and unconventional.
Another disadvantage of this route is that the vinyl alcohol (III) is difficult to crystallize from the reaction mixture and has to be purified via tedious column chromatography before being subjected to coupling with the aromatic halide under the Heck conditions Also, the large amount of emulsion formation was observed during the solvent extractive workup of the reaction of cerium chloride assisted addition of methyl magnesium chloride to Methyl-[(E)-2-[3(S)-[3-[2-[7-chloro-2-quinolinyl) ethenyl] phenyl] -3 -hydroxypropyl] benzoate (VII). It is also observed that in the formation the alcohol II involving the reaction between benzaldehyde I and alkyl magnesium halide in THF, difficulties are encountered in direct crystallization of resulting alcohol. Formation of large amounts of emulsion was encountered during the workup of the above-mentioned reaction. These operational problems lead to the wastage of lot of time in generating the desired alcohol derivative I and VIII, thereby increasing the time cycle of the process and eventually reducing productivity.
The conventional process for synthesizing Methyl-[E]-2-[3-[3-[2-(7-chloro-2- quinolinyl] ethenyl]phenyl]-3-oxopropyl]benzoate (VI) is a multistep step (6) sequence and involves the selective condensation of 7-Chloroquanaldine with isophthaldehyde in the presence of acetic anhydride under controlled stochiometric conditions to form the intermediate [E]-3-2-(7-chloro-2-quinolinyl) ethenyl]benzaldehyde (I), which upon reaction with methyl magnesium chloride or bromide in tetrahydrofuran (THF) followed by activated manganese dioxide assisted oxidation of the resulting [E]-l-[3-]2-(7-Chloro-2-quinolinyl) ethenyl]phenyl]ethanol (II) affords the aromatic ketone intermediate III in low yield. The ketone III is then benzylated with Methyl-2-bromomethyl or iodomethyl benzoate in the presence of lithium diisopropylamide at low temperatures to directly form ketoester Methyl-[E]-2-[3-[3-[2-(7-chlorq-2-quinolinyl)ethenyl]phenyl]-3- oxopropyl]benz-oate (VI) in low yields which has to be chromatographically purified in order to remove the dibenzylated compound and other impurities that are formed in appreciable amounts. Alternatively, the crude ketoester VI can be prepared in relatively higher yields via a three step route in which the ketone III sequentially undergoes facile sodium hydride induced one carbon homologation with dimethyl carbonate followed again by sodium hydride assisted benzylation of
the resulting β-ketoester IV with methyl-2-bromoethyl benzoate which is then
decarboxylated in hot acetic acid and hydrochloric acid to produce a crude mixture of VI and its corresponding acid VIA. The acid VIA is further selectively O- methylated with methyl iodide in the presence of alkali metal carbonate to yield the crude ketoester VI. The crude VI thus obtained contains very little amount of the corresponding acid (<1%) and is purified via crystallization before being used in the next stage. Use of highly moisture sensitive and explosive sodium hydride at two consecutive stages of such a short synthesis makes the scale up of synthesis of the ketoester VI very difficult and inconvenient for commercialization. Secondly, the oxidation of [E]-l-[3-]2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]ethanol (II) with stochiometric amounts of activated manganese dioxide is not very clean and does not go to completion. Purification of the reaction residue via tedious column chromatography produces the ketone III in low yields. Moreover the use of stochiometric amounts of manganese dioxide used in the transformation generates large quantities of manganese sludge on commercial scale which puts a huge load on the effluent treatment plant, thereby adding to the overall manufacturing cost. In view of the above-mentioned several drawbacks of both the iorganometallic and conventional non-organometallic routes, there exists a need for an improved, operationally convenient, environment friendly, time and cost effective process for synthesizing the key intermediates keto ester (VI), hydroxyl ester (VII) and diol (VIII) which can be scaled up and eventually result in the commercialization of a process for the production of Montelukast Sodium with increased yield and purity. BRIEF DESCRIPTION OF THE DRAWING: Figure 1 depicts the schematic representation of the process of the present invention.
SUMMARY OF THE INVENTION:
Accordingly, one of the main objects of the present invention is to provide a process, which obviates the drawbacks associated with the existing processes.
The other objective is to provide a process that is simple, easy to operate, environment friendly and high yielding.
Further, the process of this invention does not require any sophisticated equipment stringent process parameters. Yet other objective is to provide a process for the direct crystallization of the alcohol (II) from the reaction mixture avoiding the existing solvent extractive workup procedure in which extensive formation of emulsion occurs. Another object of the present invention is to develop a high yielding process for the preparation of ketone III in which the tedious column chromatographic purification is avoided.
Yet another object of the present invention is to develop a high yielding process for the preparation of III wherein the problems associated with the generated manganese sludge due to the use of stochiometric quantities of manganese dioxide and the consequent load on the effluent treatment plant are eliminated. Still other object of the present invention is to develop an alternate, safer and scaleable process for synthesizing the intermediates β- keto ester (IV) and the benzylated β- keto ester (V) by using milder reagents in place of the highly moisture sensitive and explosive reagents like sodium hydride and LDA in the transformation.
Still another object of the present invention is to develop an alternate, milder and scaleable process for synthesizing β ketoester (IV) eliminating employing additional inorganic salts and phase transfer reagents.
Still another objective of the invention is to develop reproducible reaction conditions for the preparation of chiral alcohol VII via asymmetric reduction of benzylated ketoester (VI) using reduced amount of the expensive chiral reagent (-) diisopinocamphenylchloro borane. Further objective of the present reaction is to develop an alternative workup procedure for the isolation of diol (VIII), in which the problems associated with the delays encountered during de-emulsification of the reaction work up are eliminated.
We have discovered that by reversing the mode of reaction mixture workup and by adding calculated amount of ammonium chloride and water to the reaction mixture followed by stirring at 5 to 1O0C helps in direct crystallization of the alcohol II, thereby solving the problem of emulsion formation.
We have also discovered that the oxidation of alcohol II under Swern's conditions using Lewis base instead of the one reported in presence of manganese dioxide enhances the yield of the ketone III up to 90% while maintaining purity of the product and eliminating tedious chromatographic purification.
Further, homologation of the said ketone III with dialkyl carbonate can be successfully achieved by substituting the moisture and temperature sensitive and explosive alkali metal hydride with milder agents such as alkali metal alkoxide. Similarly the benzylation also can be affected in presence of mild bases avoiding use of sodium hydride. The reaction is preferably performed in 1, 4-dioxane in the presence of sodium methoxide at 75-8O0C.
In the case of conversion of VI into VII problems were encountered as the reaction did not go as per expectations and a large excess of the expensive (-) DIPCl was needed for completing the reaction. After a considerable amount of experimentation it was observed in the present invention that the amount of solvent used in the reaction plays a key role in influencing the completion of the reaction. Higher the amount of solvent present in the mixture, the slower is the progress of the reaction. The reaction works reasonably well when conduced at -1O0C to +2O0C in the presence of 1.3 to 1.75 equivalents of (-) diisopinocamphenylchloroborane (65-75% solution in hexanes) in presence of lewis base, & in presence of 1.5 to 2.0 times v/w of aprotic solvent with respect to benzylated ketoester (VI). The problems associated with the delays encountered during de-emulsification of the reaction work up involving the Cerium Chloride assisted addition of methylmagnesiun halides to the hydroxyl ester (VII) leading to the diol (VIII), are eliminated by addition of the celite to reaction mixture thereby resulting in the facile filtration of the organic extracts with little or no emulsion formation. STATEMENT OF THE INVENTION:
Accordingly the present invention provides a process for synthesizing diol (VIII)- an intermediate of Montelukast Sodium which comprises:
(a) preparing benzaldehyde of formula I in a conventional manner, (b) reacting the said benzaldehyde I with Grignard reagent in water miscible etheral solvent to precipitate the alcohol of formula (II) by addition of ammonium salt and water followed by isolating the alcohol thus precipitated by any known methods and then oxidizing directly under "Sweπi's conditions" to get a ketone of formula III,
(c) enolizing the said ketone in presence of a mild base such as alkali metal alkoxide and then reacting it with dialkyl carbonate under conditions
effective to yield a β- ketoester of formula IV,
(d) benzylating the said β-ketoester so obtained in the preceding step to form the
benzoate of formula V in presence of mild inorganic base followed by decarboxylating the said benzoate to a mixture of a ketoester of formula VI and its corresponding acid of formula VIA in the presence of acidic conditions,
(e) alkylating the acid VIA present in the mixture in the preceding step to obtain ketoester of formula VI and purifying it if so desired,
(f) asymmetrically reducing the ketoester of formula VI, to a chiral alcohol of formula VII using (-) diisopinocamphenylchloroborane (-DIPC1) in presence of less than 4 times v/w aprotic solvent and optionally in presence of Lewis base with respect to the said ketoester of formula VI, (g) treating the said chiral alcohol VII with cerium halo salt, and alkylmagnesium halide followed by isolating the title compound using hyflow supercel and ammonium chloride to get the intermediate diol of formula VIII.
In accordance with the other aspect of this invention there is provided a process for synthesizing diol (VIII)-an intermediate of Montelukast Sodium which comprises:
(a) preparing benzaldehyde of formula I in a conventional manner,
(b) reacting the said benzaldehyde I with Grignard reagent in water miscible ethereal solvent to yield the alcohol of formula (II) by addition of ammonium salt and water ,
(c) subjecting the said alcohol to Heck coupling with methyl-2-iodobenzoate in presence of Lewis base, acetonitrile, and palladium acetate to yield ketoester
(VI),
(d) asymmetrically reducing the ketoester of formula VI, to a chiral alcohol of formula VII using (-) diisopinocamphenylchloroborane (-DIPC1) in presence of less than 4 times v/w aprotic solvent and optionally in presence of Lewis base with respect to the said ketoester of formula VI,
(e) treating the said chiral alcohol VII with cerium halo salt, and alkylmagnesium halide followed by isolating the title compound using hyflow supercel and ammonium chloride to get the intermediate diol of formula VIII. In accordance with other aspect of the present invention there is provided a process for synthesizing alcohol (II)-an intermediate of Montelukast Sodium which comprises:
(a) preparing benzaldehyde of formula I in a conventional manner,
(b) reacting the said benzaldehyde I with Grignard reagent in water miscible etheral solvent to precipitate the alcohol of formula (II) by addition of ammonium salt and water followed by isolating the alcohol thus precipitated by any known methods.
In accordance with yet other aspect of the present invention there is provided a process for synthesizing ketone (IΙI)-an intermediates of Montelukast Sodium which comprises:
(a) preparing benzaldehyde of formula I in a conventional manner,
(b) reacting the said benzaldehyde I with Grignard reagent in water miscible etheral solvent to precipitate the alcohol of formula (II) by addition of ammonium salt and water followed by isolating the alcohol thus precipitated by any known methods and then oxidizing directly under "Swern's conditions" to get a ketone of formula III,
In accordance with yet other aspect of the present invention there is provided a process for synthesizing ketoester (VΙ)-an intermediate of Montelukast Sodium which comprises: (a) preparing benzaldehyde of formula I in a conventional manner,
(b) reacting the said benzaldehyde I with Grignard reagent in water miscible etheral solvent to precipitate the alcohol of formula (II) by addition of ammonium salt and water followed by isolating the alcohol thus precipitated by any known methods and then oxidizing directly under "Swern's conditions" in presence of Lewis base, to get a ketone of formula III,
(c) enolizing the said ketone in presence of a mild base such as alkali metal alkoxide and then reacting it with dialkyl carbonate under conditions
effective to yield a β- ketoester of formula IV,
(d) benzylating the said β-ketoester so obtained in the preceding step to form the
benzoate of formula V in presence of mild inorganic base followed by decarboxylating the said benzoate to a mixture of a ketoester of formula VI and its corresponding acid of formula VIA in the presence of acidic condition,
(e) alkylating the acid VIA present in the mixture in the preceding step to obtain ketoester of formula VI and purifying it if so desired,
(f) asymmetrically reducing the ketoester of formula VI, to a chiral alcohol of formula VII using (-) diisopinocamphenylchloroborane (-DIPC1) in presence of less than 4 times v/w aprotic solvent and optionally in presence of Lewis base with respect to the said ketoester of formula VI, In one of the embodiments of the present invention, the reaction in step (a) may be carried out in presence of acetic anhydride at a temperature in the range of 90- 15O0C for a period of 10-30 hrs., preferably at 100-1100C for 12-15 hrs. In other embodiment of the present invention, Grignard reagent used may be of
formula R1MgX where R1 is alkyl with Cl to C4 exemplified by methyl, ethyl,
propyl, isopropyl, n-butyl, isobutyl or vinyl and X is halide preferably iodide,
the reaction being carried out in presence of ethereal solvent including but not restricted to 2-methoxytetrahydrofuran, tetrahydropyran, 1, 2-dimethoxyethane, 1, 2-diethoxy -ethane, preferably tetrahydrofuran or mixture thereof, at a temperature ranging from -25 to +4O0C, preferably at -5 to +1O0C.
In another embodiment of the present invention, the direct isolation and crystallization of the alcohol of formula II after workup was effected by adding calculated amount of 1 to 25% preferably 2 to 10% more preferably 10% aqueous soution of ammonium salt such as ammonium acetate, ammonium chloride, preferably ammonium chloride solution in an amount of 2 to 10 preferably 3 to 5 times of benzaldehyde (I) and water in the range of 5 to 50 preferably 10 to 15 times of benzaldehyde (I) to the reaction mixture and then straightaway crystallizing the product by stirring the mixture at -100C to 350C preferably 50C -1O0C for extended period of 2 to 10 preferably 4 to 8 hours, then isolating by centrifugation, filtration and drying.
Another embodiment of the invention is that the oxidation of alcohol (II) in step (b) being performed under Swern's conditions employing oxalyl chloride, dimethyl sulfoxide and Lewis base exemplified by alkyl amine such as triethyl amine, tri n-propylamine, tri n-butylamine, tri n-pentylamine, and diisopropyl ethyl amine preferably triethyl amine of 5 to 15 molar preferably 8 to 12 molar equivalents w. r. t the alcohol (II) as the reagents and the reaction is performed at -600C to +3O0C preferably -6O0C to +1O0C over a period of 4 to 6 hrs., employing molar equivalents of DMSO between 2 to 8, preferably 4 to 6 equivalents and that of oxalyl halide between 1.5 to 4, preferably 2 to 2.5 equivalents with respect to the alcohol (II)
Yet another embodiment of the invention is that the enolization of the ketone III
in step (c) may be effected by milder bases of formula R3OM wherein R3 is alkyl
with Cl to C3 and M is Na or K selected from alkali metal alkoxide including sodium methoxide, sodium ethoxide, sodium n-propoxides, sodium n- isopropoxide, sodium n-butoxides, sodium isobutoxide, sodium tertiary butoxide as well as their potassium salt derivatives in an amount of 1.5 to 7 molar equivalents w. r. t. to ketone with dialkyl carbonate wherein alkyl may be with Cl to C3 in an amount ranging from 2 to 8 preferably 3 to 4 molar equivalents of ketone, in polar solvents like THF, 1,2 dimethoxyethane, 1,2 diethoxyethane, dimethyl formamide, dimethyl acetamide preferably 1,4-dioxane in an amount of 2 to 10 v/w with regard to ketone at 10 to 1000C, preferably at 40 to 9O0C more preferably at 60 to 9O0C , still more preferably at 70 to 8O0C. Still another embodiment of the invention, the benzylation of the β-ketoester of formula IV in step (d) may be performed by reacting the said ketoester with alkyl- 2- halomethylbenzoate preferably methyl or ethyl and n-propyl ester derivative and halo may be chloro, bromo or iodo particularly alkyl-2-bromomethylbenzoate using much milder and safer alkali metal bases like sodium or potassium carbonates in polar aprotic solvents like dimethylformamide, dimethylacetamide, dimethylsulfoxide, hexamethylphosphorous-triamide, 1, 4 - dioxane, tetrahydrofuran, 1, 2- dimethoxyethane and 1, 2 - diethoxy -ethane etc. using 1.1 to 1.5 molar equivalents of methyl 2-bromomethyl benzoate, 1 to 3 molar, preferably 1 to 1.5 molar equivalents of anhydrous potassium carbonate and 2 to 10, preferably 3 to 5 times v/w of dry dimethylformamide w. r. t. the amount of β - keto ester (IV) 10 to 150 0C, preferably at 55 to 650C, over a period of 4 to 48 hrs, preferably over 8 to 12 hrs. The decarboxylation in step (d) is carried out using a mixture of acetic acid and hydrochloric acid in a known manner. Further, the purification may be carried out by crystallizing with 8 to 12 times acetonitrile, or with a mixture of dichloromethane and methanol 4 to 15 preferably 7 to 10 times v/w each w.r.t. ketoester. Further, the asymmetrical reduction of the ketoester VI to chiral alcohol VII may be effected by employing 1.2 to 2.0 eq. of (-) diisopinocamphenylchloroborane (-DIPC1) (65-75% solution in hexanes) in 1.5 to 4.0 times v/w of aprotic solvent exemplified by ethers such as diethyl ether, diisopropyl ether, di n-butyl ether, diisopentyl ether, anisole, cyclic ethers such as tetrahydropyran, 2- methyltetrahydrofuran, and 2-ethoxyfuran, most preferably tetrahydrofuran and the Lewis bases that may be used include but are not limited to alkyl amine like triethylamine, tri n-propylamine, tri n-butylamine, trisopropylamine, triisobutylamine, most preferably diisopropylethylamine in 0.25 to 2 molar equivalents, preferably 0.5 to 0.75 molar equivalents w. r. t. the keto ester (VI) As another embodiment of the invention, the cerium halo salt and alkylmagnesium halide used for converting the chiral alcohol VII to the diol intermediate VIII may be such as methyl or ethyl and propylmagnesium chlorides, bromides or iodides and the isolation may be undertaken by simply dumping the reaction mass into as stirred suspension of hyflow supercel in 8 to 10% ammonium salt preferably ammonium chloride followed by centrifuging or filtering through a bed of hyflow supercel. The procedure may also be carried out in the presence of water immiscible organic solvents like benzene, toluene, ortho or para xylene, and halogenated solvents like methylene dichloride, chloroform, and 1,2-dichloro ethane, which may be used in pure form or as mixtures in any suitable composition.
The Lewis base used in Heck coupling of alcohol (II) in step (c) include but are not limited to alkyl amines like triethylamine, tri n-propylamine, tri n-butylamine, diisopropyl ethyl amine, in an amount of 0.1 to 10 times preferably 0.5 to 1 times, palladium acetate used may vary from 0.1% w/w to 2.5 % w/w, preferably
0.5 to 1.5% w/w and the amount of acetonitrile may vary between 1 and 100 times, preferably 3 and 10 times v/w w. r. t the benzaldehyde (I) used. The reaction may be performed at 10 to 1000C, preferably at 65 to 750C over a period of 1 to 100 hrs, preferably for 5 to 25 hrs. The invention is further illustrated with the help of examples. However, this should not construe the scope of the invention. Any deviation from this, apparent and or obvious to an ordinary skilled person in the field forms a part of this invention though not explicitly substantiated.
General: AU chemicals used, unless otherwise specified, were of commercial
grade and were analyzed before use. IR spectrum was recorded on NICOLET- AVAATAR 320 FTIR spectrophotometer, 1H-NMR (300 MHz) and 13C-NMR (75.47 MHz) spectra were measured on Bruker DPX-300 spectrometer at ambient temperatures. EIMS spectrum were recorded onVG-70-250S mass spectrometer at NEPER, Mohalli, Punjab and RSIC, Punjab University, Chandigarh, India.
EXAMPLE 1:
Preparation of [E]-3-[2-(7-Chloro-2-quinolinyl)ethenyI]benzaldehyde (I).
To a 2.0 It. round bottom flask fitted with a mechanical stirrer, thermometer pocket and condenser were charged 7-chloroquinaldine (100 g, 0.56 mol), isophthaldehyde (90.40 g, 0.67 mol), toluene (400 ml), acetic anhydride (109.30 g,101 ml, 1.0 mol) and the mixture was refluxed at 100-1050C for 12 to 15 hours. After the reaction was over, the mixture was cooled to 25 to 3O0C; hexane (400 ml) was added to the reaction mixture and stirred for two hours. The condensed product was filtered, washed with hexane (100ml) and dried at 50 to 6O0C for 4 to 6 hours. The crude product (158 g) and ethyl acetate (2.37 It) were charged in a round bottomed flask and heated to reflux with stirring at 60 to 7O0C for 30 minutes. The hot solution was filtered through cloth and the filtrate was concentrated to almost half the volume (i.e. approximately 7 It) under vacuum. The solution was the cooled to 15 to 2O0C, stirred for two hours, filtered and washed with ethyl acetate (120 ml, 15 to 2O0C) and dried at 50 to 6O0C to obtain [E]-3-2-(7-chloro-2-quinolinyl)ethenyl]benzaldehyde (I) as a yellow crystalline solid. Melting Point 149-1510C, Yield=124.80 g (75.15 %); Purity (HPLC) =
98.96 %.
EXAMPLE 2: [EJ-l-P-PKT-Chloro-l-quinoIinyOethenylJphenyllethanoHII)
To a cooled (-10 to O0C) and stirred suspension of [E]-3-2-(7-Chloro-2- quinolinyl) ethenyljbenzaldehyde (I) (80 g, 0.27 mol) in tetrahydrofuran (500 ml) in a 2.0 lt/4 neck round bottomed flask fitted with a mechanical stirrer, thermometer pocket and calcium chloride drying tube under nitrogen gas atmosphere, methylmagnesium chloride (150 g, approx. 2.75 molar solution in THF) was added drop wise over 45 minutes keeping the temperature to -10 to 0 0C. The reaction mixture was stirred at -05 to +050C and progress of the reaction was monitored by TLC. After the reaction was over (approx 2 hours), ammonium chloride (300 ml, 10% aqueous solution) was added to reaction mixture and the reaction mixture was stirred for 30 minutes at 10 to 150C followed by slow addition of water (1000 ml). The solid thus formed was filtered, successively washed with water (2 X 250 ml) and chilled isopropyl alcohol (2 X 100ml) and dried at 50 to 6O0C for 6 to 8 hours to yield [E]-l-[3-[2-(7-chloro-2-quinolinyl) ethenyl]phenyl]ethanol (II) as a yellow solid. Melting point = 139-1410C, Yield = 75.26 g (89.43 %); Purity (HPLC) = 99.36 "/0.,1H-NMR (300 MHz, CDCl3) δ = 01.52-01.54 (d, 3H, -CH(OH)CH3); 02.34-02.28 (brs, IH5-CH(OH)CH3 exchangeable with D2O); 04.97-04.90( q, IH, -CH(OH)CH3); 07.30-08.10-(m,
HH, olefmic and aromatic H)., IR (KBr) Cm"1 = 3276, 3058, 3020, 2972, 2928, 2873, 1637, 1608, 1501, 1446, 1408, 1353, 1312, 1219, 1224, 1167, 1153, 1086, 1069, 976, 032, 869, 848, 790, 697, 620, 474. EXAMPLE 3: [EJ-l-tS-^-CT-Chloro^-quinoIinyOethenylJphenyllethanone CIII)
To a 21t/4 neck round bottom flask fitted with a mechanical stirrer, thermometer pocket, calcium chloride drying tube and nitrogen inlet were successively charged with dichloromethane (600ml), dimethylsulphoxide ( 60.50 g, 54.9 ml, 0.77 mol). The solution was cooled to -55 to -6O0C in a liquid N2/methanol slush bath and oxalyl chloride ( 45.5 g, 32 ml, 0.36 mol) in a solution of dichloromethane (165 ml) was added drop-wise over a period of 30 minutes, keeping the temperature at
-50 to -6O0C and the reaction mixture was stirred for 5 minutes under nitrogen atmosphere. A suspension of [E]-l-[3-[2-(7-chloro-2-quinolinyl) ethenyl]phenyl]ethanol (II) (50 g, 0.16 mol) dichloromethane (1.5 It.) was slowly added to the reaction mixture over 30 minutes at -50 to -60 0C and stirred for 15 minutes. Triethylamine (165 g, 225 ml, 1.63 mol) dissolved in dichloromethane
(165 ml) was slowly added over 20 minutes. After stirring for 5 minutes at -55 to -60 0C, the temperature was slowly raised to +05 to +10 0C over 30 minutes and stirred for 15 minutes when the TLC of the mixture indicated it to be complete. Water (200 ml) was added to the reaction mixture, the organic layer was separated and aqueous layer was extracted with dichloromethane (200 ml) and the combined dichloromethane layers were neutralized (pH = 7-8) with sodium bicarbonate ( approx 250-300 ml of 10% solution). Recovery of dichloromethane under vacuum provided crude residue, which was crystallized stirring in chilled isopropyl alcohol (200 ml, -5 to O0C). After 1 hour of stirring, the resulting [E]-I- [3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]ethanone (III) was filtered, washed with chilled isopropyl alcohol (100ml) and dried at 50-550C. The product thus formed was a yellow colored powder. Melting point =168-171°C ., Yield = 41.43 g (92 %); Purity (HPLC) = 99.97 %, 1H-NMR (300 MHz, CDCI3) δ = 02.66 (s, 3H, CH3); 07.40 - 08.20 (M, HH,olefinic and aromatic H):, IR (KBr) Cm"1=
3066, 3049, 3003, 3030, 2927, 1679, 1606, 1595, 1497, 1427, 1406, 1355, 1277, 1191, 1144, 1069, 988, 968, 928, 869, 839, 790, 685, 616.
EXAMPLE 4: Methyl-[E]-3-[3-[2-(7-Chloro-2-quinolinyI)ethenyl]phenyl]-3-oxopropanoate (IV). To a 2 lt/4 neck round bottom flask fitted with a mechanical stirrer, thermometer pocket, calcium chloride drying tube and nitrogen gas inlet, were successively charged , 1,4-dioxane (200ml), sodium methoxide (27.80 g, 0.51 mol) and [E]-l-[3-[2-(7-chloro-2-quinolinyl)ethenyl] phenyl] ethanone (III) (50 g, 0.16 mol) at 20 to 3O0C. After stirring for 15 to 20 minutes, dimethylcarbonate (53.45 g, 50 ml) was charged and the contents were heated at 75-80 0C for 8 to
10 hours and progress of the reaction was monitored by TLC. After the reaction was over, the temperature was lowered to 20-30 0C, water (500ml) was added and the contents were stirred for 45-60 minutes. The resulting solid was filtered, slurry washed wt water (50ml) followed by washing with chilled isopropyl alcohol (50 ml) and dried in oven at 50 to 60 0C for 4 to 6 hours to afford
Methyl- [E] -3 - [3 - [2-(7-chloro-2-quinolinyl)ethenyl]phenyl] -3 -oxopropanoate (IV) as a pale yellow powder. Melting point =117 to 1210C, Yield = 51.17 g (86.72%); Purity (HPLC) = 98.51%:, 1H-NMR (300 MHz, CDCl3 + DMSO-d6) δ = 03.76(s, 3H, OCH3); 04.12 (s, 2H, COCH2CO2CH3); 07.38-08.20 (m, HH, olefmic and aromatic H) :, IR (KBr) Cm"1 = 3426, 3108, 3066, 3030,
2999, 2954, 1759, 1656, 1609, 1593, 1498, 1446, 1407, 1385, 1336, 1276, 1253, 1215, 1176,1144, 1080, 1068, 1021, 972, 929, 911, 883, 835, 797, 729. EXAMPLE 5:
MethyI-[E]-2-[3-[3-[2-(7-Chloro-2-quinolinyl)ethenyI]phenyl]-3-(2- carboxymethyl)-oxopropyl]benzoate (V):
A 3.0 lt/4 neck round bottom flask fitted with a mechanical stirrer, thermometer pocket, calcium chloride drying tube under nitrogen gas atmosphere was successively charge with dimethylformamide (1200ml), Methyl-[E]-3-[3-[2-(7- chloro-2-quinolinyl) ethenyl]phenyl]-3-oxopropanoate (IV) (300 g, 0.82 mol), methyl-2-bromoethyl benzoate (237 g, 1.03 mol) and crushed K2CO3 (146 g, 1.05 mol) at 25 to 30 0C and the mixture was heated at 57 to 63 0C with vigorous stirring for 6 to 8 hours. After the reaction over, the mixture was cooled to 20 to
25 0C ammonium acetate solution (15% aqueous solution, 900 ml) was added slowly to quench the reaction and stirred for 1 hour. Additional water (1800 ml) was slowly added to the mixture ad stirred for 2 hours. The precipitated solid was filtered, washed with water (2400ml) and then the wet product as stirred with methanol (1800 ml) at 20 to 30 0C for 1 hr. Finally, Methyl-[E]-2-[3-[3-[2-(7-
Chloro-2-quinolinyl)ethenyl]phenyl]-3-(2- carboxymethyl)oxopropyl]benzoate (V) was filtered and washed with methanol (300 ml) and obtained as a pale yellow powder after being dried in the oven at 60-65 0C for 6-8 hours. Melting point = 119 to 1220C Yield = 368.5 g (87.77 %); Purity (HPLC) = 98.33 %:, 1H-NMR ( 300 MHz, CDCl3) δ = 03.60-03.79 (d, 2H, -CHCH2- merged with-
OCH3); 03.63 (s,3H, OCH3) 03.90 (s, 3H, OCH3); 05.05-05.09 ( t, IH, -CO-CH- (CH2)CO-); 07.24-08.22 (m, 15H, olefinic and aromatic H):, 13C-NMR (75.47 MHz, CDCl3) δ = 34.14 (CH2-C6H4CO2CH3); 52.11 (OC-CH-CO2-CH3); 52.53 (OCH3); 54.99 (OCH3); 119.67, 125.62, 126,96, 127.09, 127.39, 128.06, 128.65, 129.04, 129.32, 129.66, 131.03, 131.67, 132.16, 133.64, 135.44, 136.10, 136.83,
139.98, 146.48, 156.20 (olefinic and aromatic C); 167.55(CO), 169.77(aliphatic CO2CH3); 194.88 (aromatic CO2CH3):, IR (KBr) Cm"1 = 3066, 3021, 2952, 2843, 1751, 1711, 1677, 1607, 1576, 1498, 1436, 1337, 1303, 1285, 1266, 1157, 1134, 1084, 1067, 963,926, 871, 762,684,622.
EXAMPLE 6: Methyl-IEl-Z-IS-fS-p-CT-Chloro-l-quinolinyOethenyllphenylJ-S- oxopropyl]benzoate (VI)
Step 1: To a 2.1t/4 neck round bottom flask, fitted with mechanical stirrer, thermometer pocket and reflux condenser were successively charged glacial acetic acid (585 ml), concentrated hydrochloric acid (117 ml), Methyl-[E]-2-[3-
[3-[2-(7-Chloro-2-quinolinyl)ethenyl]ρhenyl]-3-(2- carboxymethyl)oxoρropyl]benzoate (V) (117 g, 0.22 mol) at 25 to 30 0C and the reaction mixture was heated with stirring at 60-65 0C for 10 to 12 hrs. After the reaction was over(monitored by TLC), the mixture was cooled to 25 to 30 0C, saturated ammonium chloride solution (540 ml) was slowly added to the reaction and stirred for 1 hour. The resulting crude product containing impure Methyl- [E]- 2-[3-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-oxopropyl]benzoate (VI )and its corresponding acid VIA was filtered, successively washed with water (234 ml), methanol (117 ml) and dried at 50 to 600C and was used as such in the next step. Yield = 107 g.
Step 2: To a 3 lt/4 neck round bottom flask, fitted with a mechanical stirrer, thermometer pocket, and reflux condenser were successively charged acetone (1.28 It), K2CO3 (40 g, 0.29 mol), step 1 product ( 107 g, 0.24 mol)and methyl iodide (31.5 g, 13.8 ml, 0.22 mol) at 25 to 30 0C and the reaction mixture was slowly heated to 50 to 55 0C and stirred for 6 to 8 hours. After the reaction was over( as monitored by TLC), the mixture was filtered through hyflow bed to remove the precipitated inorganic salts and the bed was washed with acetone (255 ml). Complete recovery of acetone under vacuum at 40 to 450C provided crude residue to which were successively charged dichloromethane (1.1 ml) and water (430 ml) at 20 to 25 0C. After stirring for 5 minutes, the organic layer was separated, washed with water (430ml), and evaporated at 35 to 40 0C under vacuum. To the crude residue thus obtained was charged isopropyl alcohol (270 ml) and the mixture was cooled to 0 to +05 0C and stirred for 4 to 6 hours.
Filtration followed by washing with cold IPA(IOO ml) afforded Methyl-[E]-2-[3- [3-[2-(7-chloro-2-quinolinyl)ethenyl] phenyl] -3 -oxopropyljbenzoate (VI) as a pale yellow to light brown solid; Yield = 96.5 g (69.2 % on 100 % assay basis); Purity = 99.03 %; Assay (HPLC) = 75.2 % .
Step 3:-Puriflcation of crude keto ester CVD : Method I: To a 1 lt/3 neck round bottom flask fitted with a mechanical stirrer and a thermometer pocket were charged the above crude Methyl-[E]-2-[3-[3-[2-(7-chloro-2- quinolinyl)ethenyl]phenyl]-3-oxopropyl]benzoate (VI) obtained in step 2 (45 g, ), dichloromethane (225 niL) and the mixture was stirred at 38 to 40 0C for 15 minutes, during which, complete dissolution of solid took place. Methanol (450 mL) was slowly added to the solution and the mixture was stirred for 20 minutes at 28 to 30 0C, the organic layer was decanted and tarry and oily material was separated. The above decanted solution was filtered through hyflow bed to remove small amount of suspended polymeric material and dichloromethane from the mixture was distilled off at 40 to 420C followed by stirring at 5 to 10 0C for 8 hrs. The solid thus formed was filtered, washed with chilled methanol ( 45 mL, 0 0C) and dried in oven at 50 to 550C for 6 hrs to obtain pure (VI) as a pale yellow solid. Melting point = 121 to 1240C. Yield = 30.58 g (68 %); Purity (HPLC) = 99.22 %; Assay (HPLC) = 98.14 %.
Purification of crude (VI ): Method II: : To a 500 mL/3 neck round bottom flask fitted with a mechanical stirrer and a thermometer pocket were charged the above crude VI obtained in step 2 (45 g ) and acetonitrile (450 mL) and the mixture was heated to 75-80 0C for 20 minute, during which time complete dissolution of solid took place. The solution was filtered hot through hyflow bed to remove the suspended and tarry material and then slowly cooled to 23 to 25 0C and stirred for 8 hrs at that temperature. The precipitated material was filtered and successively washed with cold acetonitrile (2 x 25 mL) and hexanes ( 45 mL) and dried at 55 to 6O0C to obtain pure Methyl-[E]-2-[3-[3-[2-(7-Chloro-2- quinolinyl)ethenyl]phenyl]-3-oxopropyl]benzoate (VI) as a light yellow to cream colored powder. Melting Point = 122 to 1240C; Yield =34.5 g (76.66 %). Purity (HPLC) = 99.52 %; Assay (HPLC) = 98.92 %. 1H-NMR (CDCI3) δ = 03.40 (bs, 4H3 -CO-CH2-CH2C6H4CO2CH3); 03.90 (s, 3H, OCH3); 07.38-08.28-(complex multiplet, 15H, olefmic and aromatic H).
EXAMPLE 7:
Methyl-[(E)]-2-[3(S)-[3-[2-[7-chloro-2-quinolinyl)ethenyI]phenyl]-3- hydroxypropyl] benzoate (VII): To a 1.0 lt/4 neck round bottom flask fitted with a mechanical stirrer, thermometer pocket and calcium chloride drying tube under nitrogen gas atmosphere were charged (-)-diisopinocamphenylchloroborane (190 mL, 65 to 75% solution in heptanes) and tetrahydrofuran at -5 to O0C for 10 minutes. Purified Methyl-[E]-2-[3-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-oxo- ρropyl]benzoate (VI) (100 g, 0.22 mol) dissolved in anhydrous THF (300 mL) was slowly added over 20 minutes and reaction mixture was allowed to stir for 6 hours at O0C and then at 12 to 150C till the reaction was complete ( 12 hours). After the reaction was over, the mixture was poured into aqueous solution of diethanolamine (3 It. of 1% solution) at 28 to 30 0C and stirred for 20 minutes followed by addition of hexanes (1 It). The mixture was stirred for 30 minutes at 30 0C, the solid was filtered, successively washed with water (2 x 200 mL), hexanes (200 mL) and dried at 40 to 45 0C for 8 hrs to yield crude hydroxyl ester (VII) as a yellow monohydrate powder. Moisture content (approx) =7.0 - 8.0% w/w, Yield = 98.31 g; Purity (HPLC) = 99.70 %; Assay (HPLC) = 95.78 %:
Purification of hydroxy ester (VII ) To a 2 .01t/3 neck round bottom flask fitted with a mechanical stirrer and a thermometer pocket were charged the above crude VII (95 g), methanol (950 mL) and triethylamine (9.5 mL) and the mixture was heated to 65 to 70 0C for 20 minutes, during which time complete dissolution of solid took place. The solution was filtered hot through hyflow bed to remove the suspended and tarry material and then 50% of methanol was distilled off slowly under normal conditions and the solution was cooled to -12 to -10 0C and stirred for 8 hrs at that temperature. The precipitated material was filtered under vacuum, washed with chilled methanol (50 mL) and dried at 55 to 6O0C to obtain pure Methyl-[(E)-2-[3(S)-[3-[2-[7-Chloro-2-quinolinyl)ethenyl]phenyl]-3- hydroxypropyljbenzoate (VII) as a light yellow colored powder. Melting point= 99 to 103 0C; Yield = 90 g (94.5 % from pure VI); Purity (HPLC) =99.85 %; Assay (HPLC) = 99.05 %. 1H-NMR (300 MHz, CDCl3) δ ( ppm) = 02.06- 02.17(t, 2H, HOCH-CH2-CH2); 03.08-03.17 (t, 2H, -HOCH-CH2CH2); 03.86 (s, 3H, OCH3); 04.74-04.77 (t, IH, OH); 07.25-07.86(complex multiplet, 15H, olefinic and aromatic H).
EXAMPLE 8:
[(E)]-2-[3(S)-[3-[2-(7-Chloro-2-quinolinyI)-ethenyl]phenyl]-3- hydroxypropyljphenyl] -2-propanol (VIII):
To a 3 lt/4 neck round bottom flask fitted with a mechanical stirrer, reflux condenser and calcium chloride drying tube under an atmosphere of nitrogen gas were charged tetrahydrofuran (1.25 It) and anhydrous cerium chloride (55 g, 0.10 mol) and the grayish white suspension was heated to reflux for 2 hours. The suspension was then cooled to -15 to -1O0C and methyl magnesium chloride (435 g, 2.75 molar solution in THF) was added drop wise over 30 minutes keeping the temperature at -5 to 0 0C and the contents were stirred for 1 hour at the same temperature. Methyl-[(E)-2-[3(S)-[3-[2-[7-Chloro-2-quinolinyl)ethenyl]phenyl]-
3-hydroxypropyl] benzoate (VII) (100 g, 0.22 mol, azeotropically dried in refluxing toluene) dissolved in toluene (1.0 It) was added drop wise over 30 minutes at -10 to 00C. The solution was stirred at 0 to +050C and the progress of the reaction was monitored by TLC. After stirring for two hours, the reaction mixture was poured into a suspension of hyflow supercel (200 g) in 10 % ammonium chloride solution (1.0 It) and stirred for 15 to 20 minutes. The above contents were filtered through hyflow bed and the bed was washed with toluene(200 ml). The organic layer was separated and the aqueous layer was extracted with toluene (200 ml) and the combined toluene were washed with water (2 X 250 ml) and dried over sodium sulphate. Complete recovery of toluene under vacuum at 50 to 55 0C provided viscous oil which was dissolved in toluene (400 ml) at 30 to 400C. Hexane (1.0 to 1.2 It) was slowly added over 30 minutes to the above solution and the mixture was stirred for 5 to 6 hours at 35 to 40 0C.
The precipitated solid was filtered, washed with hexane (500 ml) and dried at 45 to 50 0C for 4 to 6 hours to provide [(E)-2-[3(S)-[3-[2-(7-Chloro-2-quinolinyl)- ethenyl]phenyl]-3-hydroxypropyl]phenyl]-2-propanol (VIII) as a off white to light yellow powder. Melting point = 118 to 1210C:, Yield = 84.75g (84.75%); Purity (HPCL)= 99.62%; Assay (HPLC) =98.05%:, 1H-NMR (CDCl3) δ = 01.65 and 01.68 (2s, 6H, C(OH)(CH3)2; 02.13-02.17(q, 2H, -CH(OH)CH2CH2-); 03.13- 03.30(dd, 2H, CH(OH)CH2-CH2); 3.46 (bs, IH, C(OH)(CH3)2; 4.42 (bs, IH, CH(OH)CH2-); 04.69-04.71 (t, IH, CH(OH)CH2-CH2); 07.13-07.55 (complex multiplet, 15H, olefmic and aromatic H); 13C-NMR (CDCI3) δ =. 29.67 (CH3), 31.64 (CH3), 31.96(HO-CH-CH2-CH2); 41.85(HO-CH-CH2CH2); 72.82(HO-
CHCH2CH2); 73.85 (HOC(CH3)2); 119.26, 124.85, 125.43, 126.83, 127.06, 135.26, 135.93, 136.03, 140.16, 145.18, 145.47, 148.26, 156.76(aromatic C) IR (KBr) Cm"1 = 3392, 3056, 2967, 2925, 2869, 1719, 1636, 1607, 1497, 1441, 1408, 1372, 1310, 1261, 1143, 1131, 1068, 963, 929, 863,837, 787, 761, 697, 621.
EIMS m/z = 457(M+)
EXAMPLE 9: Preparation of [E]-l-[3-[2-(7-ChIoro-2-quinolinyl)ethenyl]phenyl]-2-propen- l-ol (II): To a cooled (-10 to 0 0C) and stirred suspension of [E]-3-2-(7-Chloro-2- quinolinyl)ethenyl]benzaldehyde (I) (10Og, 0.34 mol) in tetrahydrofuran (300 rnL) and toluene (1000 mL) in a 3.0 lt/4 neck round bottomed flask fitted with a mechanical stirrer, thermometer pocket and calcium chloride drying tube under nitrogen gas atmosphere, vinylmagnesium bromide (500 g, , approx. 1.0 molar solution in THF) was added drop wise over 60 minutes keeping the temperature to -10 to 00C. The reaction mixture was stirred at -15 to + 200C and progress of the reaction was monitored by TLC. After the reaction was over (approx 2 hours), ammonium acetate (600 mL, 10% aqueous solution) was added to reaction mixture and the reaction mixture was stirred for 30 minutes. The toluene layer was separated and the aqueous layer was extracted with toluene (2 x 1000 mL), the toluene layers were combined, washed with water (2x1000 mL), dried over sodium sulfate and evaporated under vacuum at 55 to 60 0C to afford crude residue of [E]-l-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]ρhenyl]-2-ρroρen-l-ol (II) which is used as such in the next stage. Yield 126 g. Purity (HPLC) =92.5 %
EXAMPLE 10: Preparation of MethyI-[E]-2-[3-[3-[2-(7-Chloro-2-quinolinyI) ethenyl] phenyI]-3-oxopropyl]benzoate (VI) To a 1.01t/4 neck round bottom flask fitted with a mechanical stirrer, thermometer pocket and calcium chloride drying tube under nitrogen gas atmosphere, were successively charged crude 1-
[3-[2-(7-Chloro-2-quinolinyl)ethenyl]ρhenyl]-2-propen-l-ol (II) (125 g, 92.5 % pure), acetonitrile, methyl-2-iodobenzoate (100 g, 0.38 mol) and triethylamine (112 mL ) and the mixture was stirred for 15 min. Palladium acetate (1.0 g ) was then added and the mixture was slowly heated to reflux at 80 to 85 0C and progress of the reaction was monitored by TLC. After the reaction was over (12- 15 hr), fresh acetonitrile was added to the reaction mixture and the hot solution was filtered through hyflow bed to remove the palladium salts and then allowed to stir at 20 to 25 0C for 8 hr by which time most of the product had precipitated out.
The solid was filtered and successively washed with cold (5 to 10 0C) acetonitrile ( 125 mL), mixture of water and acetonitrile (125 mL +125 mL each), slurry washed with cold acetonitrile (125 mL) and finally with hexanes ( 125 mL) and dried at 55 to 60 0C to afford crude keto ester (VI) as a brownish colored powder. Yield = 111.2 g ( 69.6% on 100 % basis); Purity (HPLC )
=97.21%; Assay (HPLC ) = 94.34 %).
Purification of crude keto ester ( VI) : Crude ketoester ( VI ) (110 g) was charged into acetonitrile (1100 mL) in a 2 lt/3 neck round bottom flask and the mixture was heated to 75 to 85 0C till all the material had got dissolved and then filtered hot through hyflow bed to remove the suspended and tarry material. The solution was cooled to 20 0C and stirred for 12 hrs at that temperature and the precipitated material was filtered and successively washed with cold acetonitrile (2 x 55 mL) and hexanes (110 mL) and dried at 55 to 60 0C to obtain pure Methyl-[E]-2-[3-[3-[2-(7-Chloro-2-quinolinyl) ethenyl]phenyl]-3- oxopropyl]benzoate (VI) as a light yellow to cream colored powder. 122 to 124
0C Yield = 96.5 g (62.2 % from benzaldehyde I). Purity (HPLC) = 99.5 %. Assay (HPLC) = 98.5%; 1H-NMR (CDCl3) δ = 03.40 (bs, 4H, -CO-CH2- CH2C6H4CO2CH3); 03.90 (s, 3H, OCH3); 07.38-08.28-(COnIpIeX multiplet, 15H, olefinic and aromatic H).
ADVANTAGES
❖ The process is high yielding . ❖ The process is cost effective user friendly, environmentally clean.
❖ The process is scalable and compatible for industrial application.
❖ The process does not require any stringent operational conditions. The process does not require any sophisticated infrastructure.
❖ The process leads to a title compound with high purity.

Claims

WE CLAM:
1. A process for synthesizing diol (VΙII)-an intermediate of Montelukast Sodium which comprises:
(a) preparing benzaldehyde of formula I in a conventional manner, (b) reacting the said benzaldehyde I with Grignard reagent in water miscible etheral solvent to precipitate the alcohol of formula (II) by addition of ammonium salt and water followed by isolating the alcohol thus precipitated by any known methods and then oxidizing directly under "Swern's conditions" to get a ketone of formula III, (c) enolizing the said ketone in presence of a mild base such as alkali metal alkoxide and then reacting it with dialkyl carbonate under conditions effective
to yield a β- ketoester of formula IV,
(d) benzylating the said β-ketoester so obtained in the preceding step to form the benzoate of formula V in presence of mild inorganic base followed by decarboxylating the said benzoate to a mixture of a ketoester of formula VI and its corresponding acid of formula VIA in the presence of acidic conditions,
(e) alkylating the acid VIA present in the mixture in the preceding step to obtain ketoester of formula VI and purifying it if so desired,
(f) asymmetrically reducing the ketoester of formula VI, to a chiral alcohol of formula VII using (-) diisopinocamphenylchloroborane (-DIPC1) in presence of less than 4 times v/w aprotic solvent and optionally in presence of Lewis base with respect to the said ketoester of formula VI, (g) treating the said chiral alcohol VII with cerium halo salt, and alkylmagnesium halide followed by isolating the title compound using hyflow supercel and ammonium
chloride to get the intermediate diol of formula VIII.
2. A process for synthesizing diol (VΙII)-an intermediate of Montelukast Sodium which comprises:
(a) preparing benzaldehyde of formula I in a conventional manner,
(b) reacting the said benzaldehyde I with Grignard reagent in water miscible ethereal solvent to yield the alcohol of formula (II) by addition of ammonium salt and water
(c) subjecting the said alcohol to Heck coupling with methyl-2-iodobenzoate in presence of Lewis base, acetonitrile, and palladium acetate to yield ketoester (VI),
(d) asymmetrically reducing the ketoester of formula VI, to a chiral alcohol of formula VII using (-) diisopinocamphenylchloroborane (-DIPC1) in presence of less than 4 times v/w aprotic solvent and optionally in presence of Lewis base with respect to the said ketoester of formula VI,
(e) treating the said chiral alcohol VII with cerium halo salt, and alkylmagnesium halide followed by isolating the title compound using hyflow supercel and ammonium chloride to get the intermediate diol of formula VIII.
3. A process for synthesizing alcohol (IΙ)-an intermediate of Montelukast Sodium which comprises:
(a) preparing benzaldehyde of formula I in a conventional manner,
(b) reacting the said benzaldehyde I with Grignard reagent in water miscible etheral solvent to precipitate the alcohol of formula (II) by addition of ammonium salt and water followed by isolating the alcohol thus precipitated by any known methods.
4. A process for synthesizing ketone (IΙI)-an intermediates of Montelukast Sodium which comprises:
(a) preparing benzaldehyde of formula I in a conventional manner,
(b) reacting the said benzaldehyde I with Grignard reagent in water miscible etheral solvent to precipitate the alcohol of formula (II) by addition of ammonium salt and water followed by isolating the alcohol thus precipitated by any known methods and then oxidizing directly under "Swern's conditions" to get a ketone of formula III,
5. A process for synthesizing ketoester (VΙ)-an intermediate of Montelukast Sodium which comprises:
(a) preparing benzaldehyde of formula I in a conventional manner,
(b) reacting the said benzaldehyde I with Grignard reagent in water miscible etheral solvent to precipitate the alcohol of formula (II) by addition of ammonium salt and water followed by isolating the alcohol thus precipitated by any known methods and then oxidizing directly under "Swern's conditions" in presence of Lewis base, to get a ketone of formula III,
(c) enolizing the said ketone in presence of a mild base such as alkali metal alkoxide and then reacting it with dialkyl carbonate under conditions effective to
yield a β-
ketoester of formula IV,
(d) benzylating the said β-ketoester so obtained in the preceding step to form the
benzoate of formula V in presence of mild inorganic base followed by decarboxylating the said benzoate to a mixture of a ketoester of formula VI and its corresponding acid of formula VIA in the presence of acidic condition,
(d) alkylating the acid VIA present in the mixture in the preceding step to obtain ketoester of formula VI and purifying it if so desired,
(e) asymmetrically reducing the ketoester of formula VI, to a chiral alcohol of formula VII using (-) diisopinocamphenylchloroborane (-DIPC1) in presence of less than 4 times v/w aprotic solvent and optionally in presence of Lewis base with respect to the said ketoester of formula VI,
6. A process as claimed in the preceding claim wherein the reaction in step (a) is carried out in presence of acetic anhydride at a temperature in the range of 90- 15O0C for a period of 10-30 hrs., preferably at 100-1100C for 12-15 hrs.
7. A process as claimed in the preceding claim wherein the Grignard reagent used
is of formula R1MgX where R1 is alkyl with Cl to C4 exemplified by methyl,
ethyl, propyl, isopropyl, n-butyl, isobutyl or vinyl and X is halide preferably
chloride or bromide, the reaction being carried out in presence of ethereal
solvent including but not restricted to 2-methoxytetrahydrofuran, tetrahydropyran,
1, 2-dimethoxyethane, 1, 2-diethoxy -ethane, preferably tetrahydrofuran or mixture thereof, at a temperature ranging from -25 to +4O0C, preferably at -5 to +1O0C.
8. A process as claimed in the preceding claim wherein the direct isolation and crystallization of the alcohol of formula II, in step (b), after workup is effected by adding calculated amount of 1 to 25% preferably 2 to 10% more preferably 10% aqueous solution of ammonium salt such as ammonium acetate, ammonium chloride, preferably ammonium chloride solution in an amount of 2 to 10 preferably 3 to 5 times of benzaldehyde (I) and water in the range of 5 to 50 preferably 10 to 15 times of benzaldehyde (I) to the reaction mixture and then straightaway crystallizing the product by stirring the mixture at -1O0C to 350C preferably 50C -1O0C for extended period of 2 to 10 preferably 4 to 8 hours, then isolating by centrifugation, filtration and drying.
9. A process as claimed in the preceding claim wherein the oxidation of alcohol (II) in step (b) is performed under Swern's conditions employing oxalyl chloride, dimethyl sulfoxide and Lewis base exemplified by alkyl amine such as triethyl amine, tri n-propylamine, tri n-butylamine, tri n-pentylamine, and diisopropyl ethyl amine preferably triethyl amine of 5 to 15 molar preferably 8 to 12 molar equivalents w. r. t the alcohol (II) as the reagents and the reaction is performed at -6O0C to +3O0C preferably -6O0C to +1O0C over a period of 4 to 6 his., employing molar equivalents of DMSO between 2 to 8, preferably 4 to 6 equivalents and that of oxalyl halide between 1.5 to 4, preferably 2 to 2.5 equivalents with respect to the alcohol (II).
10. A process as claimed in the preceding claim wherein the enolization of the
ketone III in step (c) is effected by milder bases of formula R3OIVI wherein R3 is
alkyl with Cl to C3 and M is Na or K selected from alkali metal alkoxide including sodium methoxide, sodium ethoxide, sodium n-propoxides, sodium n- isopropoxide, sodium n-butoxides, sodium isobutoxide, sodium tertiary butoxide as well as their potassium salt derivatives in an amount of 1.5 to 7 molar equivalents w.r.t. ketone with dialkyl carbonate wherein alkyl may be with Cl to C3 in an amount ranging from 2 to 8 preferably 3 to 4 molar equivalents of ketone, in polar solvents like THF, 1,2 dimethoxyethane, 1,2 diethoxyethane, dimethyl formamide, dimethyl acetamide preferably 1,4-dioxane in an amount of
2 to 10 v/w with regard to ketone at 10 to 1000C, preferably at 40 to 9O0C more preferably at 60 to 9O0C , still more preferably at 70 to 8O0C.
11. A process as claimed in the preceding claim wherein the benzylation of the β- ketoester of formula IV in step (d) is performed by reacting the said ketoester with alkyl-2- halomethylbenzoate preferably methyl or ethyl and n-propyl ester derivative and halo may be chloro, bromo or iodo particularly alkyl-2- bromomethylbenzoate using much milder and safer alkali metal bases like sodium or potassium carbonates in polar aprotic solvents like dimethylformamide, dimethylacetamide, dimethylsulfoxide, hexamethylphosphorous-triamide, 1, 4 - dioxane, tetrahydrofuran, 1, 2- dimethoxyethane and 1, 2 - diethoxy -ethane etc. using 1.1 to 1.5 molar equivalents of methyl 2-bromomethyl benzoate, 1 to 3 molar, preferably 1 to 1.5 molar equivalents of anhydrous potassium carbonate and 2 to 10, preferably 3 to 5 times v/w of dry dimethylformamide w. r. t. the amount of β - keto ester (IV) 10 to 150 0C, preferably at 55 to 650C, over a period of 4 to 48 hrs, preferably over 8 to 12 hrs.
12. A process as claimed in the preceding claim wherein the decarboxylation in step (d) is carried out using a mixture of acetic acid and hydrochloric acid in a known manner and the purification is conducted by crystallizing with 8 to 12 times acetonitrile, or with a mixture of dichloromethane and methanol 4 to 15 preferably 7 to 10 times v/w each w.r.t. ketoester.
13. A process as claimed in the preceding claim wherein the asymmetrical reduction of the ketoester VI to chiral alcohol VII is effected by employing 1.2 to 2.0 equivalents of (-) diisopinocamphenylchloroborane (-DIPC1) (65-75% solution in hexanes) in 1.5 to 4.0 times v/w of aprotic solvent exemplified by ethers such as diethyl ether, diisopropyl ether, di n-butyl ether, diisopentyl ether, anisole, cyclic ethers such as tetrahydropyran, 2-methyltetrahydrofuran, and 2- ethoxyfuran, most preferably tetrahydrofuran and the Lewis bases that may be used include but are not limited to triethylamine, tri n-propylamine, tri n- butylamine, trisopropylamine, triisobutylamine, most preferably diisopropylethylamine in 0.25 to 2 molar equivalents, preferably 0,5 to 0.75 molar equivalents w. r. t. the keto ester (VI).
14. A process as claimed in the preceding claim wherein the cerium halo salt and alkylmagnesium halide used for converting the chiral alcohol VII to the diol intermediate VIE is selected from methyl or ethyl or and propylmagnesium chlorides, bromides or iodides and the isolation is undertaken by simply dumping the reaction mass into as stirred suspension of hyflow supercel in 8 to 10% ammonium salt preferably ammonium chloride followed by centrifuging or filtering through a bed of hyflow supercel.
15. A process as claimed in claim 2 wherein the Lewis base used in Heck coupling of alcohol (H) in step (c) include but are not limited to alkyl amines like triethylamine, tri n-propylamine, tri n-butylamine, diisopropyl ethyl amine, in an amount of 0.1 to 10 times preferably 0.5 to 1 times, palladium acetate used may vary from 0.1% w/w to 2.5 % w/w, preferably 0.5 to 1.5% w/w and the amount of acetonitrile may vary between 1 and 100 times, preferably 3 and 10 times v/w w.
r. t the benzaldehyde (I) used and the reaction is performed at 10 to 100 C,
preferably at 65 to 750C over a period of 1 to 100 hrs, preferably for 5 to 25 hrs.
16. A process for synthesizing diol (VIII), alcohol (IT), ketone(HI), and ketoester (VI) an intermediates of Montelukast Sodium substantially as herein described with reference to the examples and drawings.
PCT/IN2005/000280 2004-08-23 2005-08-22 A process for synthesizing diol (viii)-an intermediate of montelukast sodium WO2006021974A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1561/DEL/2004 2004-08-23
IN1561DE2004 2004-08-23

Publications (1)

Publication Number Publication Date
WO2006021974A1 true WO2006021974A1 (en) 2006-03-02

Family

ID=35427726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000280 WO2006021974A1 (en) 2004-08-23 2005-08-22 A process for synthesizing diol (viii)-an intermediate of montelukast sodium

Country Status (1)

Country Link
WO (1) WO2006021974A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035379A2 (en) * 2006-09-19 2008-03-27 Aptuit Laurus Private Limited Process for and intermediates of leukotriene antagonists
WO2008135966A1 (en) * 2007-05-02 2008-11-13 Chemagis Ltd. Process for the purification of optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxy-propyl)phenyl-2-propanol
EP2094665A2 (en) * 2006-11-06 2009-09-02 Dr. Reddy's Laboratories Ltd. Preparation of montelukast and its salts
US7812168B2 (en) 2005-07-05 2010-10-12 Teva Pharmaceutical Industries Ltd. Purification of montelukast
WO2011026398A1 (en) * 2009-09-02 2011-03-10 山东新时代药业有限公司 Synthetic method of montelukast sodium intermediate
WO2011042416A1 (en) * 2009-10-09 2011-04-14 Dsm Ip Assets B.V. Sythesis of optically active intermediate for the preparation of montelukast
US8088610B2 (en) 2007-09-28 2012-01-03 Codexis, Inc. Ketoreductases for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hroxypropyl)benzoate
WO2012020271A1 (en) 2010-08-11 2012-02-16 Richter Gedeon Nyrt. Process for the preparation of montelukast sodium
US8207343B2 (en) 2008-05-26 2012-06-26 Laurus Labs Private Limited Process for preparing montelukast and salts thereof
CN102702097A (en) * 2012-05-16 2012-10-03 浙江大学 Preparation method of montelukast sodium intermediate
CN103073492A (en) * 2013-02-04 2013-05-01 中国科学院上海有机化学研究所 Synthesis method of 2-(3-(S)-(3-(2-7-chlorine-2-quinolyl) vinyl) phenyl)-3-hydroxypropyl) benzoate
CN103936671A (en) * 2014-05-06 2014-07-23 启东东岳药业有限公司 Preparation method for montelukast sodium intermediate
CN104109122A (en) * 2013-04-16 2014-10-22 浙江奥翔药业有限公司 Intermediate compound for synthesizing montelukast, and preparation method thereof
CN104496899A (en) * 2015-01-15 2015-04-08 安润医药科技(苏州)有限公司 Synthesis method of midbody of Montelukast sodium
CN106928136A (en) * 2017-02-23 2017-07-07 济南大学 A kind of Graphene palladium cobalt sequential catalyst synthesizes the method for MK intermediate

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0480717A1 (en) * 1990-10-12 1992-04-15 Merck Frosst Canada Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
WO1995018107A1 (en) * 1993-12-28 1995-07-06 Merck & Co., Inc. Process for the preparation of leukotriene antagonists
US5545758A (en) * 1994-08-11 1996-08-13 Merck & Co., Inc. Process for the preparation of diisopinocampheylchloroborane
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5869673A (en) * 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0480717A1 (en) * 1990-10-12 1992-04-15 Merck Frosst Canada Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
WO1995018107A1 (en) * 1993-12-28 1995-07-06 Merck & Co., Inc. Process for the preparation of leukotriene antagonists
US5614632A (en) * 1993-12-28 1997-03-25 Merck & Co., Inc. Process for the preparation of leukotriene anatgonists
US5545758A (en) * 1994-08-11 1996-08-13 Merck & Co., Inc. Process for the preparation of diisopinocampheylchloroborane
US5869673A (en) * 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CONLON, D.A.; ET AL., ADV. SYNTH. CATAL., vol. 346, 2004, pages 1307 - 1315, XP009058825 *
KING, A.O.; ET AL., J. ORG. CHEM., vol. 58, no. 14, 1993, pages 3731 - 3735, XP002358965 *
ZHAO M ET AL: "A Convenient and Economical Method for the Preparation of DIP-Chloride<TM> and Its Application in the Asymmetric Reduction of Aralkyl Ketones", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 38, no. 15, 14 April 1997 (1997-04-14), pages 2641 - 2644, XP004058293, ISSN: 0040-4039 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812168B2 (en) 2005-07-05 2010-10-12 Teva Pharmaceutical Industries Ltd. Purification of montelukast
WO2008035379A3 (en) * 2006-09-19 2010-02-18 Aptuit Laurus Private Limited Process for and intermediates of leukotriene antagonists
WO2008035379A2 (en) * 2006-09-19 2008-03-27 Aptuit Laurus Private Limited Process for and intermediates of leukotriene antagonists
EP2094665A2 (en) * 2006-11-06 2009-09-02 Dr. Reddy's Laboratories Ltd. Preparation of montelukast and its salts
EP2094665A4 (en) * 2006-11-06 2010-11-24 Reddys Lab Ltd Dr Preparation of montelukast and its salts
WO2008135966A1 (en) * 2007-05-02 2008-11-13 Chemagis Ltd. Process for the purification of optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxy-propyl)phenyl-2-propanol
US8617853B2 (en) 2007-09-28 2013-12-31 Codexis, Inc. Ketoreductase polypeptides for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxypropyl)benzoate
US8088610B2 (en) 2007-09-28 2012-01-03 Codexis, Inc. Ketoreductases for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hroxypropyl)benzoate
US8207343B2 (en) 2008-05-26 2012-06-26 Laurus Labs Private Limited Process for preparing montelukast and salts thereof
US8367834B2 (en) 2008-05-26 2013-02-05 Laurus Labs Private Limited Process for preparing Montelukast and salts thereof
WO2011026398A1 (en) * 2009-09-02 2011-03-10 山东新时代药业有限公司 Synthetic method of montelukast sodium intermediate
CN101638381B (en) * 2009-09-02 2012-08-29 鲁南制药集团股份有限公司 Synthesis method of montelukast sodium intermediate
JP2013503822A (en) * 2009-09-02 2013-02-04 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 Synthetic method of Montelukast sodium intermediate
US8569508B2 (en) 2009-09-02 2013-10-29 Shandong New Time Pharmaceutical Co., Ltd. Synthetic method for montelukast sodium intermediate
KR101459301B1 (en) 2009-09-02 2014-11-07 산동 뉴 타임 파마슈티칼 코., 리미티드. Synthetic method of montelukast sodium intermediate
WO2011042416A1 (en) * 2009-10-09 2011-04-14 Dsm Ip Assets B.V. Sythesis of optically active intermediate for the preparation of montelukast
CN102574803A (en) * 2009-10-09 2012-07-11 帝斯曼知识产权资产管理有限公司 Sythesis of optically active intermediate for the preparation of montelukast
WO2012020271A1 (en) 2010-08-11 2012-02-16 Richter Gedeon Nyrt. Process for the preparation of montelukast sodium
CN102702097A (en) * 2012-05-16 2012-10-03 浙江大学 Preparation method of montelukast sodium intermediate
CN103073492A (en) * 2013-02-04 2013-05-01 中国科学院上海有机化学研究所 Synthesis method of 2-(3-(S)-(3-(2-7-chlorine-2-quinolyl) vinyl) phenyl)-3-hydroxypropyl) benzoate
CN104109122B (en) * 2013-04-16 2017-03-29 浙江奥翔药业股份有限公司 For synthesizing midbody compound of montelukast and preparation method thereof
CN104109122A (en) * 2013-04-16 2014-10-22 浙江奥翔药业有限公司 Intermediate compound for synthesizing montelukast, and preparation method thereof
CN103936671A (en) * 2014-05-06 2014-07-23 启东东岳药业有限公司 Preparation method for montelukast sodium intermediate
CN103936671B (en) * 2014-05-06 2015-10-28 启东东岳药业有限公司 The preparation method of montelukast sodium intermediate
CN104496899A (en) * 2015-01-15 2015-04-08 安润医药科技(苏州)有限公司 Synthesis method of midbody of Montelukast sodium
CN106928136A (en) * 2017-02-23 2017-07-07 济南大学 A kind of Graphene palladium cobalt sequential catalyst synthesizes the method for MK intermediate
CN106928136B (en) * 2017-02-23 2019-05-10 济南大学 A kind of method of graphene palladium cobalt sequential catalyst synthesis montestron sodium intermediate

Similar Documents

Publication Publication Date Title
WO2006021974A1 (en) A process for synthesizing diol (viii)-an intermediate of montelukast sodium
Ronco et al. Improved synthetic pathway for the derivatization of huprine scaffold
JP2022130510A (en) Method for producing cis-alkoxy substituted spirocyclic 1-h-pyrrolidine-2,4-dione derivatives
US7271268B1 (en) Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
AU2007346135B2 (en) Process for the preparation of 2-substituted-5-(1-alkylthio) alkylpyridines
EP1375487B1 (en) Process for producing quinoline-3-carboxylic acid compounds
EP0990647A1 (en) Process for producing quinolone derivatives
CN103936718B (en) A kind of preparation method of high-purity delafloxacin
US9611217B2 (en) Synthetic processes of carprofen
AU600838B2 (en) Process for the preparation of dextrorotatory 3-(3-pyridyl)-1H, 3H-pyrrolo(1,2-c)-7-thiazolecarboxylic acid
JPH0770037A (en) Production of cyanoacylcyclopropane compound and 2-cyanoacyl-4-butanolide compound used therefor
JPS63264439A (en) Production of 3,5,6-trifluoro-4-hydroxyphthalic acid
WO2019117179A1 (en) Method for producing quinoline-4(1h)-one derivative
EP0725785B1 (en) Process for the preparation of rufloxacin and salts thereof
JP2711435B2 (en) Novel 2,3-dihydro-4H-1-benzopyran-4-one derivative or salt thereof
CN109456257B (en) Preparation method of high-yield 2-chloro-5-nitropyridine
WO1995009165A1 (en) PROCESS FOR PRODUCING 2-SUBSTITUTED BENZO[b]THIOPHENE
JP4165110B2 (en) Preparation of 4-oxypyrimidine derivatives
JP6212462B2 (en) Method for producing 3,4,5-tricaffeoylquinic acid
JP4449211B2 (en) 6- (1-fluoroethyl) -5-iodo-4-pyrimidone and process for producing the same
JP2001158774A (en) Method for producing 6-trifluoromethylnicotinic acids
EP1809609B1 (en) Process for the production of pyrimidine-5-carboxylates
JP3325139B2 (en) Method for producing thienyl ether derivative
JP2006342150A (en) 6-methylnicotinic acid phenyl ester and method for producing the same
WO2006080256A1 (en) Processes for producing 1-(6-methylpyridin-3-yl)-2-[4­(methylsulfonyl)phenyl]ethanone and intermediate for production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase